Therapy Areas: AIDS & HIV
Horizon Therapeutics Names Rosén as EVP of Research and Development, Chief Scientific Officer
3 November 2020 - - Ireland-based biopharmaceutical company Horizon Therapeutics plc (NASDAQ: HZNP) has hired Karin Rosén, M.D., Ph.D as executive vice president, research and development and chief scientific officer, reporting directly to Tim Walbert, chairman, president and chief executive officer, the company said.

Dr. Rosén is an accomplished life sciences executive and physician with nearly three decades of experience that includes directing biologic clinical research and development and building, leading and successfully launching multiple novel medicines in the United States and globally.

Prior to Horizon, she was senior vice president, US medical affairs at GlaxoSmithKline (NYSE: GSK), where she led a team of more than 300 physicians and medical professionals in disease areas including immunology, respiratory and inflammation.

Prior to GlaxoSmithKline, Dr. Rosén was senior vice president, US and global medical affairs at Aimmune Therapeutics, Inc. as well as a member of the clinical development leadership team working on the Phase 2b-3/4 clinical programs and US FDA and European Medicines Agency filing strategies.

Prior to Aimmune, Dr. Rosén was therapeutic area head, immunology, at Genentech, a member of the Roche Group.

During her tenure at Genentech, she also served as lead medical director responsible for developing Phase 2-3 clinical programs for multiple biologics in the areas of immunology, respiratory, allergy and dermatology.

Dr. Rosén received her medical degree and doctorate from Lund University in Lund, Sweden.

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases.


Related Headlines